It can be subdivided into gastric and non-gastric cases.[1] Antibiotic eradication of Helicobacter pylori (HP) has become an effective therapy for patients with gastric MALT lymphoma, and the disease usually has a favorable prognosis.[2] However, API2/MALT1-positive MALT lymphoma in the stomach is often refractory to HP eradication therapy, and has a significantly higher recurrence rate.[3]. Here, BIRC3 is linked to gastric mucosa-associated lymphoid tissue lymphoma.